Role of FLT3 Inhibitors and Other Novel Agents in AML

The importance of FLT3 inhibitors in AML and factors to consider when choosing between these agentsПодробнее

Dr. Ross Levine on deciphering and targeting clonal evolution in myeloid malignanciesПодробнее

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical PathwaysПодробнее

Advances and unanswered questions in AML: novel agents, MRD assessment, and immunotherapyПодробнее

Novel treatment combinations for FLT3-mutated AMLПодробнее

Acute Myeloid Leukemia and the Role of FLT3 Inhibitors: Best Practices for the Interprofessional ...Подробнее

Novel FLT3 inhibitors for AMLПодробнее

FLT3 inhibitors - their role in AMLПодробнее

Establishing the Role of FLT3 Mutations in AMLПодробнее

Emerging Role of FLT3 Inhibitors in AML: MidostaurinПодробнее

The use of FLT3 inhibitors in AMLПодробнее

Promising novel agents in AML: menin inhibitorsПодробнее

Role of FLT3 inhibitors as maintenance following transplant in AMLПодробнее

An overview of the safety profile of FLT3 inhibitors in AMLПодробнее

How novel agents & individualized treatment approaches are improving outcomes in patients with AMLПодробнее

Optimizing the use of FLT3 inhibitors in AML: sequencing, post-transplant maintenance & moreПодробнее

Novel potent and selective FLT3 inhibitorsПодробнее

How the AML treatment landscape is changing with the introduction of novel targeted agentsПодробнее

Advances in the management of fit adults with AMLПодробнее

Novel agents in trials for AML: quizartinib and gilteritinibПодробнее